Current/ Expected Orderbook/ Pending Orders?

The company has expanded its opportunity funnel to over 100+ active opportunities, up from 70 in Q1, indicating a healthy and growing orderbook. There are 10 molecules already signed in the CDMO business, with one molecule already supplied and others in various stages of supply ramp-up. Another 10+ opportunities are in advanced stages of discussion, expected to convert into confirmed orders in coming quarters. For the new CDMO molecules, revenues typically ramp up from 15-20% in Year 1, to 40-60% in Year 2, and reach peak (80-100%) by Year 3. Early order bookings following EU anti-dump

Any current/future new fundraising through debt or equity?

Recent capital expenditures have been primarily funded through internal accruals. The company incurred INR59 crore in capex during the latest quarter and INR109 crore year-to-date. Planned capex for FY 2026 is approximately INR600 crore, which will also be supported by internal accruals. There is no mention of any current or planned fundraising through debt or equity in the disclosed earnings call transcript. The net debt-to-EBITDA ratio stands at 1.24x, indicating manageable leverage. Overall, Jubilant Ingrevia currently relies on internal accruals for funding its growth and capex without any

Any current/future capex/capital investment/strategic investment?

INR59 crore capex incurred in the quarter, primarily towards the upcoming CDMO Agro plant at Bharuch and new multipurpose facility in Gajraula. Planned investment of approximately INR600 crore in FY '26, funded largely through internal accruals. Commissioning of $300 million Agro-Innovator CDMO project expected by Q4 FY '26. New boiler commissioning at Bharuch scheduled for Q3 FY '26 to enhance operational efficiency. Debottlenecking capacity in existing plants by 15-20% to support new CDMO and Fine Chemical volumes. Groundbreaking of new multipurpose plant at Gajraula to add flexibility and c

Future growth expectations in sales/revenue/volumes?

Expecting steady growth across segments with pipeline of 100+ active opportunities and 50+ products under development. Anticipate INR1,200 crore peak annual revenue from 10+ new CDMO and Fine Chemical molecules, contributing revenue from FY '26 and ramping up over 2-3 years. FY '26 includes launch of 18 new products aligned with market needs. Nutrition segment volume growth seen in vitamin B3 and B4, with strong traction in cosmetic grade sales. Anti-dumping duties on China creating new export opportunities, especially for choline chloride in Europe. Capacity expansions, including new multipur

Future growth expectations in earnings/operating earnings/profits/EPS?

Expectation to achieve INR1,200 crore peak annualized revenue from 10+ new CDMO molecules in 2-3 years, including a major $300 million (INR500 crore annual) contract starting early next year. EBITDA growth supported by cost optimization initiatives, with lean savings program targeting INR100 crore per year ongoing and robust. Specialty Chemicals segment margins steady at ~26%, Nutrition segment margins expected to improve from current 12%-14% to 16%-18% with mix changes. Overall EBITDA grew 8% YoY in Q2 FY '26; half-year EBITDA increased 18%, PAT surged 34% YoY. Target INR2,000 crore EBITDA by

IN US

Sale is live|00:00:00left today

Jubilant Ingrevia LtdQ3 FY25Chemicals & Petrochemicals

Jubilant Ingrevia Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹632P/E: 42.4Market Cap: ₹11.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Expecting steady growth across segments with pipeline of 100+ active opportunities and 50+ products under development.
→Anticipate INR1,200 crore peak annual revenue from 10+ new CDMO and Fine Chemical molecules, contributing revenue from FY '26 and ramping up over 2-3 years.
→FY '26 includes launch of 18 new products aligned with market needs.
→Nutrition segment volume growth seen in vitamin B3 and B4, with strong traction in cosmetic grade sales.
→Anti-dumping duties on China creating new export opportunities, especially for choline chloride in Europe.
→Capacity expansions, including new multipurpose plant at Gajraula and semiconductor R&D facility, planned to support growth from 2026-27 onward.
→Ongoing cost optimization and lean savings program supporting margin expansion amid pricing pressures.
→Renewable energy integration and operational efficiencies expected to reduce energy costs further.
→Overall confident in sustaining top line and margin growth over coming quarters.

Margin guidance

Category 3

→Expectation to achieve INR1,200 crore peak annualized revenue from 10+ new CDMO molecules in 2-3 years, including a major $300 million (INR500 crore annual) contract starting early next year.
→EBITDA growth supported by cost optimization initiatives, with lean savings program targeting INR100 crore per year ongoing and robust.
→Specialty Chemicals segment margins steady at ~26%, Nutrition segment margins expected to improve from current 12%-14% to 16%-18% with mix changes.
→Overall EBITDA grew 8% YoY in Q2 FY '26; half-year EBITDA increased 18%, PAT surged 34% YoY.
→Target INR2,000 crore EBITDA by FY 2030 from CDMO and related businesses.
→Continuous cost control and efficiency programs expected to enhance margins.
→R&D investments increasing, especially in Specialty and Nutrition segments, supporting future product launches and revenue growth.
→Renewable energy initiatives and new boiler commissioning to reduce energy costs and improve operating profits.

3 more insights locked — sign up free to unlock

Fundraise plans

→Recent capital expenditures have been primarily funded through internal accruals.
→The company incurred INR59 crore in capex during the latest quarter and INR109 crore year-to-date.
→Planned capex for FY 2026 is approximately INR600 crore, which will also be supported by internal accruals.
→There is no mention of any current or planned fundraising through debt or equity in the disclosed earnings call transcript.
→The net debt-to-EBITDA ratio stands at 1.24x, indicating manageable leverage.
→Overall, Jubilant Ingrevia currently relies on internal accruals for funding its growth and capex without any announced plans for debt or equity fundraising.

Order book

Yes

→The company has expanded its opportunity funnel to over 100+ active opportunities, up from 70 in Q1, indicating a healthy and growing orderbook.
→There are 10 molecules already signed in the CDMO business, with one molecule already supplied and others in various stages of supply ramp-up.
→Another 10+ opportunities are in advanced stages of discussion, expected to convert into confirmed orders in coming quarters.
→For the new CDMO molecules, revenues typically ramp up from 15-20% in Year 1, to 40-60% in Year 2, and reach peak (80-100%) by Year 3.
→Early order bookings following EU anti-dumping duties (e.g., choline chloride) have started and the pipeline looks healthy for Nutrition business.
→The $300 million Agro-Innovator project is on track for Q4 commissioning, expected to contribute to order fulfillment and revenues from 2026 onwards.

Capex plans

Yes

→INR59 crore capex incurred in the quarter, primarily towards the upcoming CDMO Agro plant at Bharuch and new multipurpose facility in Gajraula.
→Planned investment of approximately INR600 crore in FY '26, funded largely through internal accruals.
→Commissioning of $300 million Agro-Innovator CDMO project expected by Q4 FY '26.
→New boiler commissioning at Bharuch scheduled for Q3 FY '26 to enhance operational efficiency.
→Debottlenecking capacity in existing plants by 15-20% to support new CDMO and Fine Chemical volumes.
→Groundbreaking of new multipurpose plant at Gajraula to add flexibility and capacity in CDMO portfolio.
→Development of a state-of-the-art Semiconductor R&D facility in Greater Noida, aimed at innovation in semiconductor chemicals.
→Plans for a pilot plant in semiconductor chemicals in near future, details to be announced in due course.

How does Jubilant Ingrevia Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Jubilant Ingrevia Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Jubilant Ingrevia Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio